PRGO heads into the summer with a contradictory setup: short interest near a monthly high, yet the borrow market is loosening and the ORTEX short score is drifting lower — a split signal that makes the stock harder to read than the headline numbers suggest.
The short side of the ledger is the first thing to confront. Short interest has climbed roughly 8% over the past month to reach 10.6% of the free float — a level that is genuinely elevated and warrants attention. The pace of that build has paused this week, with shorts easing back about 2.3% from last week's peak, but the 30-day trend is still pointed upward. Against that, the borrow market tells a more relaxed story. Availability has widened back toward 374% — well into what would be considered a normal lending environment — and cost to borrow has dropped nearly 30% on the week to just 0.40%. That combination — high short interest but loose and cheap borrows — suggests the position is being maintained rather than squeezed. The ORTEX short score has slipped from 64.9 on May 29 to 57.5 today, consistent with that easing pressure.
Options positioning is calm. The put/call ratio is running at 0.38, only marginally above its 20-day average of 0.35 and well below the 52-week high of 0.97. At roughly 0.6 standard deviations above normal, there is no meaningful demand for downside protection visible in the options market — a notable contrast with a stock that carries double-digit short interest. The lending and options data together suggest the bears who hold this position are comfortable rather than urgent.
The Street view is cautious and has been trending that way for some time. Analyst data here carries a caveat — the most recent changes on record are from February 2026 at best, with the bulk of activity concentrated in late 2025. The overall direction of that activity was relentlessly negative: JP Morgan downgraded from Overweight to Neutral in November 2025, cutting its target in half from $32 to $20; Canaccord, which retains a Buy, has repeatedly trimmed its target from $42 down to $17. The consensus mean target of $16.50 implies roughly 48% upside from the current $11.18 price, but that gap reflects how far the stock has fallen rather than fresh conviction. The stock trades at just 5x earnings and 0.54x book — a valuation that is either a deep value setup or a value trap depending on whether the business stabilises. EV/EBITDA at 7.5x has drifted slightly lower over the past month, and the dividend score ranks in the 98th percentile of the universe — though the last dividend on record was paid in mid-2022, so that metric likely reflects historical yield rather than an active payout.
On the institutional side, Neuberger Berman added nearly 2.9 million shares as of the March quarter-end, a meaningful addition relative to their existing position. Millennium built roughly 2.3 million shares in the same period. Both moves suggest at least some active managers were buying the dislocation at higher prices — whether they remain comfortable at $11 is not visible in the current data. Insider activity this week was technically mixed: the CEO received an equity award and sold 12,906 shares at $10.83 — a routine tax-withholding pattern on a restricted stock vesting rather than a discretionary sale. The net 90-day insider balance is a modest positive at about $527,000, with no large-scale disposals.
Earnings are scheduled for August 5. The last two reports produced a split result — a small gain on the day in Q1 2026 followed by a 6% decline over five days, and a 4.5% single-day drop on the prior print. The next print is less about whether Perrigo can beat a low bar and more about whether the company's over-the-counter and store-brand business can show any margin recovery, given the stock has shed roughly 5% over the past month and short interest has been quietly building throughout.
See the live data behind this article on ORTEX.
Open PRGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
